49. Systemic lupus erythematosus
827 clinical trials, 638 drugs (DrugBank: 168 drugs), 108 drug target genes, 191 drug target pathways
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-INR-17011495 | 2017-05-25 | 2017-05-26 | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus | Primary mild to moderate systemic systemic lupus erythematosus | Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.; | The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology | NULL | Recruiting | Both | Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30; | China | |||
| 2 | NCT03155477 (ClinicalTrials.gov) | June 10, 2016 | 13/5/2017 | Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D | Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) Serum | SLE | Dietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placebo | Saiful Anwar Hospital | NULL | Completed | 18 Years | 45 Years | Female | 39 | N/A | NULL |
| 3 | NCT01709474 (ClinicalTrials.gov) | June 2013 | 16/10/2012 | Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus | Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IU | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Terminated | 5 Years | 20 Years | All | 7 | Phase 2 | United States |
| 4 | NCT01911169 (ClinicalTrials.gov) | June 2011 | 22/7/2013 | Vitamin D to Improve Endothelial Function in SLE | Vitamin D Repletion to Improve Endothelial Function in Lupus Patients | Atherosclerosis;Systemic Lupus Erythematosus | Drug: Cholecalciferol | Medical University of South Carolina | NULL | Completed | 18 Years | 80 Years | All | 9 | Phase 2 | United States |
| 5 | NCT01425775 (ClinicalTrials.gov) | April 2010 | 18/8/2011 | The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: vitamin D 25(OH)D;Other: Placebo | Faculty of Medicine, University of Alexandria | NULL | Completed | 18 Years | 60 Years | Both | 248 | N/A | Egypt | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01413230 (ClinicalTrials.gov) | January 2010 | 24/6/2011 | Vitamin D Supplementation in Systemic Lupus Erythematosus | Evaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus | Vitamin D Deficiency | Drug: cholecalciferol | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | Both | 20 | N/A | France |
| 7 | NCT00710021 (ClinicalTrials.gov) | November 2008 | 1/7/2008 | Vitamin D3 in Systemic Lupus Erythematosus | Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02) | Systemic Lupus Erythematosus;SLE;Lupus | Drug: Vitamin D3;Drug: Vitamin D3 placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Completed | 18 Years | N/A | All | 57 | Phase 2 | United States |
| 8 | NCT00418587 (ClinicalTrials.gov) | December 2006 | 4/1/2007 | Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE) | Phase 1 Study of Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: Cholecalciferol | Medical University of South Carolina | American College of Rheumatology Research and Education Foundation;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | 85 Years | All | 18 | Phase 1 | United States |